 SOUTH SAN FRANCISCO, Calif., March 10, 2022 GLOBE NEWSWIRE -- Tempest Therapeutics, Inc. Nasdaq: TPST, a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17, 2022 at 10:40 a.m. ET. 